Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to evaluate the efficacy of intravenous iron supplementation in the prevention of anemia in patients receiving (neo)adjuvant breast cancer regimens.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy

NCT05800600

Anemia

RECRUITING PHASE2

Treatment for Patients Suffering From Anemia Due to Chemotherapy

NCT00120692

Breast Cancer Anemia

COMPLETED PHASE2

Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy

NCT00224068

Anemia

COMPLETED PHASE4

Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced

NCT00210002

Neoplasms Anemia

TERMINATED PHASE2

Darbepoetin Alfa With or Without Intravenous (IV) Iron

NCT00401544

Anemia Non-Myeloid Malignancies

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

no iron supplentation

Group Type NO_INTERVENTION

No interventions assigned to this group

iron supplement

Group Type EXPERIMENTAL

ferric hydroxide saccharate

Intervention Type DRUG

single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ferric hydroxide saccharate

single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NORIPURUM

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women older than 18 years
2. Patient with operated breast cancer with indication for (NEO)adjuvant therapy
3. They must have hemoglobin levels within the normal range (\> 12g/dL), absence of renal and hepatic dysfunction as assessed by serum levels of urea, creatinine, AST, ALT.
4. Lack of folic acid deficiency and vitamin B12
5. Able to provide written informed consent.

Exclusion Criteria

1. Use of any oral supplement containing iron;
2. Patients who have iron overload as defined by serum ferritin\> 800 microg / L or transferrin saturation\> 40%;
3. Patients who are pregnant or breastfeeding;
4. History of active infection or active bleeding except menstruation;
5. History of HIV or hepatitis B or C - clinically important; -

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No